Humphrey et al., analyzed by immunohistochemistry, a series of 28 rhabdomyosarcomas (8 alveolar and 20 embryonal) and showed that CD44 positive patients had improved outcomes compared with CD44 negative tumors (p=0.001, Fisher test) (162). The gene discussed is CD44; the disease is rhabdomyosarcoma.